Document detail
ID

doi:10.1186/s12894-023-01300-y...

Author
Bai, Peide Zhang, WenZhao Lai, Longhui Huang, Haichao Qin, Jiaxuan Duan, Bo Wang, Huiqiang Chen, Yuedong Jia, Yuanyuan Xing, Jinchun Wang, Tao Chen, Bin
Langue
en
Editor

BioMed Central

Category

Urology

Year

2023

listing date

8/2/2023

Keywords
... cystinuria xanthine stones genetic testing cystinuria stones
Metrics

Abstract

Background Cystinuria and xanthinuria are both rare genetic diseases involving urinary calculi.

However, cases combining these two disorders have not yet been reported.

Case Presentation In this study, we report a case of cystinuria with xanthine stones and hyperuricemia.

The 23-year-old male patient was diagnosed with kidney and ureteral stones, solitary functioning kidney and hyperuricemia after admission to the hospital.

The stones were removed by surgery and found to be composed of xanthine.

Conclusion Genetic testing by next-generation sequencing technology showed that the patient carried the homozygous nonsense mutation c.1113 C> A (p.Tyr371*) in the SLC3A1 gene, which was judged to be a functionally pathogenic variant.

Sanger sequencing revealed that the patient’s parents carried this heterozygous mutation, which is a pathogenic variant that can cause cystinuria.

The 24-h urine metabolism analysis showed that the cystine content was 644 mg (<320 mg/24 h), indicating that the patient had cystinuria, consistent with the genetic test results.

This case shows that cystinuria and xanthine stones can occur simultaneously, and provides evidence of a possible connection between the two conditions.

Furthermore, our findings demonstrate the potential value of genetic testing using next-generation sequencing to effectively assist in the clinical diagnosis and treatment of patients with urinary calculi.

Bai, Peide,Zhang, WenZhao,Lai, Longhui,Huang, Haichao,Qin, Jiaxuan,Duan, Bo,Wang, Huiqiang,Chen, Yuedong,Jia, Yuanyuan,Xing, Jinchun,Wang, Tao,Chen, Bin, 2023, Declaration: Novel SLC3A1 mutation in a cystinuria patient with xanthine stones: a case report, BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw